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Abstract: A triplet repeat expansion leading to transcriptional silencing of the FMR1 gene results in
fragile X syndrome (FXS), which is a common cause of inherited intellectual disability and autism.
Phenotypic variation requires personalized treatment approaches and hampers clinical trials in
FXS. We searched for microRNA (miRNA) biomarkers for FXS using deep sequencing of urine and
identified 28 differentially regulated miRNAs when 219 reliably identified miRNAs were compared
in dizygotic twin boys who shared the same environment, but one had an FXS full mutation, and the
other carried a premutation allele. The largest increase was found in miR-125a in the FXS sample,
and the miR-125a levels were increased in two independent sets of urine samples from a total of 19
FXS children. Urine miR-125a levels appeared to increase with age in control subjects, but varied
widely in FXS subjects. Should the results be generalized, it could suggest that two FXS subgroups
existed. Predicted gene targets of the differentially regulated miRNAs are involved in molecular
pathways that regulate developmental processes, homeostasis, and neuronal function. Regulation of
miR-125a has been associated with type I metabotropic glutamate receptor signaling (mGluR), which
has been explored as a treatment target for FXS, reinforcing the possibility that urine miR-125a may
provide a novel biomarker for FXS.
Keywords: disease biomarker; urine miRNA; fragile X syndrome; autism; miR-125a
1. Introduction
MicroRNAs (miRNAs) are short (19–24 nucleotides in length) noncoding RNAs that regulate
translation by promoting mRNA degradation and attenuating protein translation [1,2]. Active
trafficking of miRNAs contributes to intercellular communication by local control of miRNA-mediated
regulation of target genes and signaling events. Several miRNAs reach the circulation using microvesicle-
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dependent or RNA-binding-protein-associated active secretion or by passive leakage from cells [3].
Measurable levels of miRNAs can be isolated from bodily fluids, including urine [4]. Mounting evidence
indicates that miRNAs are involved in the pathophysiology of several disorders, and disease-specific
extracellular miRNA profiles have been identified [5]. Changes in circulating miRNAs have been
implicated in metabolic crosstalk between organs as well as in neurodegeneration [6,7]. The accessibility
and stability of circulating miRNAs support their use as biomarkers for patient stratification to improve
the efficacy of targeted treatments [3].
Fragile X syndrome (FXS) is the most common cause of inherited intellectual disability and the
best-known single-gene cause of autism spectrum disorder, with a prevalence of 1/4000 males and
~1/6000 females. The behavioral phenotype of FXS includes hyperactivity, attention disorders, social
anxiety and mood instability, and abnormalities in sensory stimuli [8,9]. The severity of these features,
as well as responses to current pharmacological treatments, varies individually. Epilepsy associates
with FXS in about 15%–20% of FXS males [10]. In most cases, expansion of a triplet CGG repeat
in the untranslated region of the FMR1 gene from the normal 5–55 repeat range to >200 leads to
transcriptional silencing and lack of FMR1 protein (FMRP), which results in FXS [11]. A CGG repeat
between 55 and 200 triplets is a fragile X premutation that can be inherited from the mother as an
expanded full mutation [12]. Premutation carriers do not show early-childhood-onset intellectual
disability syndrome, and paradoxically, they have abnormally high levels of FMR1 mRNA, which
predisposes them to a late-onset neurodegenerative disorder called fragile X-associated tremor/ataxia
syndrome (FXTAS) [13].
FMRP expression is widespread with high abundant expression in neurons and testes [14]. The
absence of functional FMRP impairs normal synaptic formation and plasticity in the central nervous
system (CNS) and results in macro-orchidism due to the overproduction of Sertoli cells in testes [9,15].
FMRP is a messenger RNA (mRNA)-binding protein and controls protein translation by interacting with
specific mRNAs. FMRP also associates with miRNAs and proteins incorporated into a multiprotein
complex called an RNA-induced silencing complex (RISC). There is evidence that disruption of miRNA
pathways contributes to the abnormal synaptogenesis in FXS [16–18]. A RISC consisting of miR-125a
and FMRP on postsynaptic density-95 (PSD-95) mRNA has been identified as a selective mechanism
that controls PSD-95 mRNA translation for signaling of group 1 metabotropic glutamate receptors
(mGluR) at synapses [19]. Expression of miR-125a is decreased in synaptoneurosomes in the brain of
Fmr1 knockout (KO) mice, indicating that dysregulation of miR-125a is involved in impaired synapse
function in FXS. DeMarco et al. showed very recently that phosphorylation status of FMRP regulates
the stability of the miR-125a-guided RISC and PSD-95 mRNA complex [18]. Since mGluR signaling
alters FMRP phosphorylation, augmented mGluR signaling in FXS may affect turnover and/or cellular
cycling [20] of miR-125a.
We compared urine miRNA profiles of a boy with FXS and his twin brother, a premutation carrier,
and found 28 differentially expressed miRNAs. The most pronounced increase was found in levels
of miR-125a in urine of the FXS twin as well as a larger group of FXS donors. A detailed analysis of
miR-125a levels revealed an age-dependent increase in control urine, whereas the scattered distribution
of FXS samples suggested that two subgroups of FXS subjects might exist. Our results implicate
miR-125a dysregulation in the pathophysiology of FXS, consistent with previous studies of FXS mice,
and provide evidence that urine miR-125a could be a potential novel biomarker in FXS clinical trials.
2. Materials and Methods
2.1. Human Urine Samples
The research using human urine was approved by the Ethics Committee of Helsinki and Uusimaa
Hospital District and by the Ethics Committee of the Regional University Hospital of Málaga. Written
informed consent was signed by parents and donors to obtain human samples. One set of urine
samples was collected from males and a female with FXS (n = 9), a premutation carrier (n = 1; the
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twin boy), and healthy controls (n = 8) recruited under auspices of Rinnekoti Foundation. Another
independent set of urine samples obtained from control (n = 8) and FXS donors (n = 10) was analyzed
at the Regional University Hospital of Malaga (Spain) for replication purposes. The APHS Biobank has
coordinated the collection, processing, management and assignment of the biological samples used
in this study, according to the standard procedures established for this purpose. Morning urine was
collected in preservation tubes (Norgen Biotek Corp, Thorold, ON, Canada) and stored at 4 ◦C until
miRNA extraction.
FXS molecular diagnostics was performed on blood samples and the detection of CGG repeats
in the FMR1 gene was made using the Fragile X PCR test (Abbott Laboratories, IL, USA). The triplet
repeat primed PCR assay provided accurate sizing of CGG repeats; size accuracy on 5–70 CGG repeat
alleles + 1 CGG repeat and on 71–230 repeat alleles 3 CGG repeats by capillary electrophoresis, alleles
> 231 resolved by agarose gel with low accuracy for sizing, according to the kit information provided
by the manufacturer.
2.2. RNA Extraction and Quantitative Real-Time PCR
Urine miRNAs were extracted with Urine microRNA Purification Kit (Norgen Biotek Corp.,
Ontario, Canada) according to the manufacturer’s instructions. Isolated miRNA samples were eluted
in 40 µl of RNase-free water. RNA concentrations were measured with Nanodrop Spectrophotometer
(Thermo Scientific, Wilmington, DE, USA) and equal amounts of miRNA (10 ng) were used in reverse
transcription reactions. The levels of mature miRNAs were analyzed using individual TaqMan
microRNA Assays (Applied Biosystems, Life Technologies Ltd., Carlsbad, CA, USA) according to the
manufacturer’s instructions. Specific miRNA primers were used to reverse-transcribe 10 ng of total
miRNA with the TaqMan MicroRNA Reverse Transcription Kit (Applied Biosystems, Life Technologies
Ltd., Carlsbad, CA, USA) with specific primers (Table S1). The expression levels of miRNAs were
analyzed by quantitative real-time PCR (RT-qPCR) in 96-well plates on Light Cycler 480 II Real-Time
PCR System (Roche Diagnostics GmbH, Mannheim, Germany). The TaqMan probes (FAM) were
detected with 465–510 nm. The miRNAs were normalized to mean Ct values of all studied miRNAs in
a urine sample, as previously reported [21,22].
2.3. Deep Sequencing
Fragment libraries were prepared for each sample with TruSeq Small RNA Library Prep Kit
(Illumina) and sequenced using the HiSeq 2500 system (Illumina, Inc., San Diego, CA, USA) as
instructed by the manufacturer. Read lengths were 36 bases.
2.4. Analysis of Data
Raw sequence data were imported in CLC Genomics Workbench (version 7.0.3; https://www.
qiagenbioinformatics.com/) for read quality inspection, adapter trimming, and miRNA annotation
based on miRBase (http://www.mirbase.org/). The count data grouped on mature miRNAs were
then exported to R/Bioconductor v. 3.1.0 (www.bioconductor.org) (R Core Team, 2015), where the
normalization and statistical testing were carried out with the DESeq2 package [23]. The sequencing
dataset was deposited in the GEO database (accession #GSE143347).
Differentially expressed miRNAs were filtered requiring absolute fold-change > 2 and Wald test
p-value < 0.05. Target gene and pathway analysis was carried out using miRSystem [24] and DAVID
gene annotation tool [25]. In miRNA system, queried miRNAs were first converted to the last miRBase
annotation (version 17) and significantly enriched signaling pathways were identified. In addition
to the hypergeometric p-values, empirical p-values of each function/pathway were determined by
ranking the enriched hypergeometric probability as compared with null baseline probabilities [24]. The
weight of a miRNA was determined by dividing the absolute expression value of the miRNA by the
absolute sum of the expression values of all input miRNAs. Thereafter, the ranking score was obtained
by summation of the weight of miRNA times its enrichment –log (p-value) from the predicted target
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genes. Linear regression analysis of urine miR-125a levels was performed using GraphPad Prism 5.0.
Data are expressed as the mean + SEM and were analyzed for statistical significance using Student’s t
test. A p-value < 0.05 was considered significant.
3. Results
3.1. Profiling of FXS Urine miRNAs by Deep Sequencing
To uncover FXS-specific alterations in urine miRNAs, miRNA-sequencing of urine samples
obtained from individuals with and without FXS was performed by massive parallel sequencing
using a HiSeq 2500 system. The initial analysis provided evidence of age-dependent clustering of
FXS samples, although the sequencing read counts were highly variable across subjects. The donors
included seven-year-old twin boys whose total urine miRNA reads were similar, suggesting less
variation in metabolic and epigenetic measures affecting miRNA levels. One of the twin boys was
diagnosed with FXS by molecular diagnostics of >200 CGG repeats (300 repeats) in the FMR1 gene,
while the other twin boy without clinical FXS diagnosis carried CGG repeats in the range of the FMR1
gene premutation (175 repeats). The comparison of urine of the twin boys revealed 28 differentially
regulated miRNAs in a total of 219 miRNAs analyzed with >50 read counts each (Figure 1A). Of
those 28 notable miRNAs, 8 were upregulated and 20 were downregulated in FXS urine compared to
non-FXS urine (Figure 1B). The largest increase was found in the levels of hsa-miR-125a-5p.
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twin boy found by deep sequencing (Figure 2A). The miR-125a levels were 1.6-fold higher in urine 
of the FXS twin boy than those of his twin brother, and an identical increase was seen in replicate 
samples taken one year after the first sampling. The miR-125a levels were also found to be increased 
in a larger number of FXS samples from donors with a homogenous Finnish genetic heritage (Table 
Figure 1. Profiling of fragile X syndrome (FXS) urine miRNAs by deep sequencing. (A) Comparison of
identified urine miRNAs in urine of FXS full mutation (FXS) male and premutation (PreMt) carrier to
controls (CNTRL). (B) Differentially expressed miRNAs in urine of the FXS boy compared to that of his
twin brother.
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3.2. Increased miR-125a in Urine of Children with FXS
The RT-qPCR analysis confirmed the abnormal increase in miR-125a levels in urine of the FXS
twin boy found by deep sequencing (Figure 2A). The miR-125a levels were 1.6-fold higher in urine of
the FXS twin boy than those of his twin brother, and an identical increase was seen in replicate samples
taken one year after the first sampling. The miR-125a levels were also found to be increased in a larger
number of FXS samples from donors with a homogenous Finnish genetic heritage (Table 1) compared
to healthy controls (Figure 2B). The data were normalized to miR-182 that was not regulated in the
sequencing analysis, and the increase was more pronounced when miR-16 was used for normalization
consistent with the reduction of miR-16 in FXS urine in the sequencing analysis (Figure 2C).
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Figure 2. Increase in miRNA-125a levels in FXS urine. (A) Comparison of miR-125a levels in urine
of the FXS boy vs. his twin brother by deep sequencing. (B) A bar graph showing the increase in
the levels of miR-125a in urine of FXS subjects compared to controls normalized by miR-182 and (C)
after normalization with miR-16. Control (n) = 8; FXS (n) = 9. Data are expressed as the eans SE .
sterisks indicate a statistically significant difference (p < 0.05) ith Student’s t test.
miR-125a urine an lysis was replicated in an indepen ent pool of FXS urine samples collected
by a Spanish lab at t e Regional University Hospital f M aga-IBIMA. The comparison of urine
samples of Spanish FXS children (n = 10) aged 2–7 years and healthy controls (n = 8) aged 2–6 years
confirmed the 1.6-fold increase (p = 0,01) in m R-125a leve s in urine: control 13.9 (SD = 3.7, SEM =
1.51) and FXS 22.5 (SD = 2.9, SEM = 1.02). The lev ls of miR-182 did not iffer between FXS and control
samples. Altog ther, he data suggested that urin miR-125a levels were differentially gulat d in FXS
urine compared to those of healthy controls, consistent with the previous studies that have hown
FMRP-d pende t regulation of miR-125a.
Table 1. Summary of he FMR1 mutatio s and medications of the nine Finnish FXS donors.
Subject/phenotype Age; Years Gender Repeat Length Medication
FXS1 4 male mosaic
FXS2 5 male >200 risperidone, methyphenidate
FXS3 6 male 86/520 methylphenidate
FXS4 6 male >200
FXS5 8 ale >200
FXS6 8 male 300 oxcarbatzepine
FXS7 13 male >200 methylphenidate
FXS8 14 female 34/500
FXS9 17 male 300
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3.3. Age-Dependent Dysregulation of miR-125a in Urine of Children with FXS
The relative levels of miR-191 and miR-93 did not differ between FXS and control urine in the
expanded pool of samples (Figure 3A), suggesting that the miRNA differences identified in urine of
twins were small and that miRNA levels may show high variability. The difference of urine miR-125a
levels between FXS and control urine was confirmed in two sets of samples, increasing the reliability of
the results, and larger studies are needed to explore the impact of the other miRNAs identified to be
dysregulated individually. Furthermore, since urine miRNAs of premutation carrier and FXS twin
boys were initially compared, the assessment of the role of each miRNA has to be done in a set of
samples which includes both premutation carriers and FXS individuals.
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Figure 3. Distribution of miRNA levels. (A) Levels of miR-191 and (B) miR-93 did not statistically
differ between control and FXS urine. Control (n) = 8; FXS (n) = 9. (C) Age-dependent relative levels of
miR-125a in urine of healthy donors (Control) and FXS cases. (D) The variation of the slope of the lines
(95 confident band). Data are expressed as means ± SEM.
The distribution of miR-125a in urine of healthy children aged 4–18 years (n = 5) showed an
age-dependent linear increase (1.559*X – 2.147; R2 = 0.779; p = 0.0473) whereas the miR-125 levels in
FXS samples were scattered (Y = −0.648*X + 29.18; R2 = 0.074; p = 0.478), and the samples did not
correlate (Pearson’s correlation r = −0.209) (Figure 3B). Urine miR-125a levels of two FXS boys were
lower than the levels of controls and other 5 FXS donors, while all other FXS donors had higher urine
miR-125a levels than the age-matched controls. The small sample size in the study associated with a
high variation of the slope of the line in the analysis of FXS samples, leading to significant limitations
in the interpretation of the results. However, the distribution of urine miR-125a samples indicated a
possibility that the FXS samples could be d vided into two gr ups, but larger studies are needed to
investigate and possibly confirm the potential of miR-125a as a tool for stratification of FXS males.
In our set of samples, low levels of urine miR-125a did not associate with genetic mosaicism of
the FMR1 full mutation, and there was no correlation between urine miR-125a levels and specific
pharmacological intervention in the sample pool (Table 1). Levels of miR-125a w re low in urine of
a 17-year-old FXS boy with no medications as well as in urine of a 5-year-old FXS boy treated with
risperidone for aggressive behavior combined with methylphenidate for hyperactivity. On the other
hand, urine miR-125a levels were abnormally increased in two FXS donors with methylphenidate
treatment for hyperactivity. The controls did not have any medications. Only one FXS boy (FXS6) had
epilepsy, and his miR-125a levels were in the range of the high FXS values.
3.4. Target Gene and Pathway Analysis of miRNAs Regulated Differentially in FXS Urine
We analyzed predicted target genes and pathways associated with the miRNAs that were
differentially regulated in urine of the FXS twin boys using miRSystem and DAVID gene annotation
tool as shown in the summary of the sequencing data analysis in Figure 4 (http://mirsystem.cgm.ntu.
edumiRNAs) [24,25].
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Target gene analysis of increased miRNAs (all but miR-103b-1) identified 2322 possible targets.
Genes targeted by five miRNAs included gamma-aminobutyric acid (GABA) A receptor, beta 2 (GABRB2)
and StAR-related lipid transfer (START) domain containing 13 (STARD13), and genes targeted by 4 miRNAs
included BCL2L2, BDNF, GRIN3A, among others (Table 2). Metabotropic glutamate receptor 3 (GRM3)
was targeted by two miRNAs.
We chose 132 genes targeted by three or more miRNAs that were increased in FXS urine for initial
pathway analysis using DAVID gene annotation tool24, GO term, and KEGG pathway annotations [26].
We found nine KEGG pathway terms enriched with these genes: MAPK signaling pathway, pathways
in cancer, Wnt signaling pathway, focal adhesion, glioma, chronic myeloid leukemia, neurotrophic
signaling pathway, pancreatic cancer, and TGF-beta signaling pathway. The miRsystem tool found 514
pathways where the miRNAs were involved. A functional annotation summary of pathways of six
enriched miRNAs is shown in Table 3.
Table 2. Target gene analysis of increased miRNAs.
Target Gene Gene Description Observed Number ofmiRNA
STARD13 StAR-related lipid transfer (START) domain containing13 5
GABRB2 gamma-aminobutyric acid (GABA) A receptor, beta 2 5
BDNF brain-derived neurotrophic factor 4
CECR6 cat eye syndrome chromosome region, candidate 6 4
CNOT6 CCR4-NOT transcription complex, subunit 6 4
CRK v-crk avian sarcoma virus CT10 oncogene homolog 4
DPF2 D4, zinc and double PHD fingers family 2 4
DVL3 dishevelled segment polarity protein 3 4
ELOVL6 ELOVL fatty acid elongase 6 4
EPHA4 EPH receptor A4 4
FIGN fidgetin 4
BCL2L2 BCL2-like 2 4
FOXP1 forkhead box P1 4
GRIN3A glutamate receptor, ionotropic, N-methyl-D-aspartate 3A 4
IGF2BP2 insulin-like growth factor 2 mRNA binding protein 2 4
IL1RAPL1 interleukin 1 receptor accessory protein-like 1 4
KCNA1 potassium voltage-gated channel, shaker-relatedsubfamily, member 1 (episodic ataxia with myokymia) 4
MTF1 metal-regulatory transcription factor 1 4
MYCBP MYC binding protein 4
ONECUT2 one cut homeobox 2 4
RASL10B RAS-like, family 10, member B 4
SORT1 sortilin 1 4
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Table 3. Functional annotation summary (miRSystem) of pathways for 6 upregulated miRNAs in
FXS urine.
Database Pathway Target Genes Score
REACTOME Developmental Biology 105 3.663
REACTOME Axon guidance 72 3.588
KEGG MAPK signaling pathway 67 3.212
REACTOME L1CAM interactions 32 3.050
KEGG Pathways in cancer 73 2.827
BIOCARTA Biocarta MAPK pathways 31 2.802
REACTOME Interaction between L1 and ankyrins 13 2.585
REACTOME Fatty acid triacylglycerol and ketonebody metabolism 22 2.563
KEGG WNT signaling pathway 36 2.559
REACTOME Neuronal system 59 2.365
PATHWAY INTERACTION
DATABASE
Neurotrophic factor-mediated Trk
receptor signaling 16 2.331
KEGG Focal adhesion 48 2.328
KEGG Glioma 20 2.323
KEGG Chronic myeloid leukemia 20 2.307
KEGG Neurotrophin signaling pathway 29 2.241
PATHWAY INTERACTION
DATABASE C-myb transcription factor network 26 2.237
REACTOME Signaling by NGF 49 2.194
KEGG Pancreatic cancer 21 2.138
KEGG TGF-beta signaling pathway 28 2.129
PATHWAY INTERACTION
DATABASE
Signaling events regulated by Ret
tyrosine kinase 11 2.103
REACTOME NGF signaling via TrkA from Plasmamembrane 37 2.057
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The pathway ranking summary revealed that all six miRNAs were involved in nine pathways:
signaling by insulin receptor, focal adhesion, MAPK signaling pathway, neurotrophin signaling
pathway, signaling to ERKs, pathways in cancer, signaling by NGF, NGF signaling via TrkA from the
plasma membrane, and hemostasis (Table 4).
Table 4. Pathway ranking summary (miRSystem) of pathways targeted by upregulated miRNAs
identified in FXS urine.
Database Pathway Genes Raw Empirical
REACTOME Signaling by insulin receptor 4 1.41372e-2 5.07712e-2
KEGG Focal adhesion 6 7.34030e-3 3.22732e-2
KEGG MAPK signaling pathway 7 8.68277e-3 8.62286e-2
KEGG Neurotrophin signaling pathway 6 2.23557e-2 1.32203e-1
REACTOME Signaling to ERKs 3 3.57835e-3 3.10591e-2
KEGG Pathways in cancer 5 9.69353e-2 3.33703e-1
REACTOME Signaling by NGF 6 1.14105e-2 5.61302e-2
REACTOME NGF signaling via TrkA from plasma membrane 5 6.46094e-3 1.29899e-2
REACTOME Hemostasis 5 1.66621e-1 3.67254e-1
Pathway analysis of miR-125a showed similarities to the predicted pathways of the group
of increased miRNAs, including pathways of developmental biology, adaptive immune system,
hemostasis, transmembrane transport of small molecules, GPCR ligand binding, cell cycle mitotic,
cancer, neuroactive ligand-receptor activation, and class A1 of rhodopsin-like receptors (Table 5).
Furthermore, the predicted pathways for increased and reduced miRNAs showed similarities. MAPK
signaling pathway and pathways in cancer and developmental biology had the highest scores in the
pathway ranking summary for the reduced miRNAs.
Table 5. Pathway analysis (miRSystem) of miR-125a.
Database Pathway Genes Raw Empirical
REACTOME Developmental Biology 494 8.78e-4 3.89749e-1
REACTOME Adaptive immune system 482 2.519e-2 2.90419e-1
REACTOME Hemostasis 467 6.955e-3 3.12984e-1
REACTOME Transmembrane transport of small molecules 427 1.07902e-1 5.3854e-1
REACTOME GPCR ligand binding 410 1.5103e-2 5.7303e-2
REACTOME Cell cycle mitotic 330 1.06856e-1 4.15975e-1
KEGG Pathways in cancer 325 3.1018e-2 5.8577e-1
KEGG Neuroactive ligand receptor activation 318 9.2561e-2 2.12222e-1
REACTOME Class A1 (Rhodopsin-Like receptors) 305 6.7227e-2 2.74648e-1
4. Discussion
The present study identified FXS-specific changes in urine miR-125a. The levels of miR-125a were
found to be abnormally increased in FXS urine when urine samples of twin boys and an expanded
pool of donors collected in two independent labs were compared. Previous studies have demonstrated
that regulation of miR-125a is affected in the absence of FMRP, which stressed the potential importance
of urine dysregulation of miR-125a among 28 differentially regulated miRNAs identified by deep
sequencing. Levels of miR-125a are shown to be reduced in synaptoneurosomes isolated from the FXS
mouse brain [19], and the phosphorylation state of FMRP regulates the stability of miR-125a-guided
RISC-PSD 95 mRNA complex, which is critical for synapse function [18]. Increased urine miR-125a
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levels may reflect increased production and/or secretion of miR-125a, but it is not possible to make any
direct correlations between human urine and mouse brain miRNA levels. Furthermore, a detailed
analysis of miR-125a levels in children’s urine revealed an age-dependent regulation, whereas FXS
samples did not show linear correlation indicating higher individual variability. Urine miR-125a levels
of two FXS males were lower than those of the healthy controls and of five other FXS males. There was
no clear correlation between the miR-125a levels and the length of the repeat expansion in the FMR1
gene, genetic mosaicism, or pharmacological interventions within the small set of samples. The FXS
children with low levels of miR-125a in urine may present a subgroup whose cellular homeostasis
differs from that of the subgroup with higher levels of miR-125a. A well-described association between
miR-125a- and mGluR5 signaling [19] suggests that urine miR-125a levels may provide a novel tool to
subgroup FXS children based on individual differences linked particularly to mGluR5 signaling, which
is considered to be the most critically dysregulated signaling pathway in FXS.
Expression of miR-125a is high in the ovary, epididymis, spleen, and in some endocrine organs and
regions of the brain (www.microRNA.org). There is evidence that members of the miR-125 family can
have disease-suppressing properties, implying that it could predict disease onset or have prognostic
value during disease progression [27,28]. Recently ectopic expression of miR-125a was found to
promote granulocyte differentiation, and improved understanding of miR-125a function may assist in
the development of novel miR-125a-targeted therapies [29]. A role for miR-125a-5p has been identified
in the regulation of endothelial tightness, supporting the potential of miR-125a as a disease biomarker
in circulating biofluids [28,30]. There is evidence that miR-125a reduces endothelin-1 expression
and immune cell eﬄux in inflammation. It has been shown that miR-125a regulates the secretion
of some inflammatory cytokines (interleukin (IL)2, IL6, TNF-alpha, and TNF-beta) [31]. In mouse
in vivo and in vitro models of thyroiditis, an increased miR-125a expression reduces autophagy and
cell proliferation and increases the apoptotic rate and the expression of proinflammatory factors tumor
necrosis factor-α, IL-1β, IL-6, and IL-18 via downregulation of the phosphoinositide 3-kinase/protein
kinase B/mammalian target of rapamycin (PI3K/Akt/mTOR)signaling pathway [32]. Low levels of
miR-125a-5p are found in different types of tumors [33]. Levels of miR-125a-5p are also found to
be decreased in the hippocampus of rats with pentylenetetrazol (PTZ)-induced epilepsy, whereas
miR-125a-5p overexpression can attenuate seizures and decrease inflammatory factors in these rats [34].
In the present study, a total of 219 miRNAs with the expression of more than 50 read counts were
identified in human urine by RNA seq. At least a 1.5-fold expression difference cutoff is suggested by
several miRNA profiling studies that have explored the impact of changes of miRNA levels on cellular
biology [35]. We observed 28 differentially expressed miRNAs in urine of an FXS boy compared to
urine of his twin brother. The most increased miRNA in FXS urine was miR-125a, and its increase
was confirmed by RT-qPCR. The smaller increase of miR-191 levels and reduction of miR-93 levels in
FXS urine were not confirmed in the expanded pool of samples, suggesting that urine miRNA levels
are low and show high individual variability affecting their analysis. Therefore, dysregulation of the
miRNAs other than miR-125a remains to be investigated in a larger set of samples which include both
premutation carriers and FXS individuals. A panel of circulating miRNAs may have more potential to
show efficacy than single miRNAs in drug response monitoring as observed in biomarker studies of
cancer patients [19]. Many predicted target genes of the differentially regulated miRNAs were shown
to be involved in pathways that regulate molecular and cellular processes known to be disrupted in
FXS, including axon guidance and neurotrophin signaling in the nervous systems. The data suggest
that urine miRNA levels may reflect common pathological miRNA-dependent processes caused by the
absence of FMRP in multiple tissues [36].
Although most miRNAs are intracellular, significant levels of miRNAs appear outside cells
and circulate in human body fluids, including urine [4,20,37]. Each body fluid has its own miRNA
composition, but the origin of circulating miRNAs is not well understood, although correlations
between circulating and tissue miRNAs exist [38]. There is evidence that miRNAs can reach the
circulation from active secretion or passive leakage from broken cells [3]. Certain miRNAs are targeted
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for export and actively secreted to extracellular fluids [39]. Active miRNA secretion can be mediated
via microvesicles or a microvesicle-free, RNA-binding protein-dependent pathway. The majority of
urinary miRNAs originate from renal and urethral cells, but other tissues can also actively release
circulating extracellular miRNAs packaged in exosomes (lipid vesicles) [40] or bound to RNA-binding
proteins [35,41] into urine via renal epithelial cells. Interestingly, the profiles of miRNAs in urine and
cerebrospinal fluid show many similarities, such as low miRNA abundance [4]. Both cell-free and
exosomal preparations are found in urine samples [3], and the small number of miRNAs may indicate
that only distinct miRNAs are stabilized by microvesicles or associated with RNA-binding protein
and high-density lipoprotein (HDL) as a carrier and protected from degradation by ribonucleases in
the circulation.
The present study did not examine correlations of miR-125a levels in urine and other bodily fluids.
Previously slight but not significant reduction of miR-125a-5p was observed in FXTAS patients’ blood
by deep sequencing [42]. The miRNA profiling of serum in children with autism spectrum disorder
(ASD) identified thirteen differentially expressed miRNAs in individuals with ASD compared to the
controls, and miR-125a was not among the dysregulated miRNAs [43].
There are 12 brain miRNAs identified to interact with FMRP [16], and these miRNAs
include miR-125a. Involvement of miR-125a in fate determination of neuronal lineages [44] and
synaptic plasticity [45] links dysregulation of miR-125a to FXS but potentially also to several other
neurodevelopmental disorders. Differential expression of miR-125a in the male and female frontal
lobe region during normal development has been reported [46], and many similar sexually dimorphic
miRNAs are associated with autism-related diseases and processes [47]. Gender effects on the analysis
of FXS urine miR-125a levels were reduced in the current study by using only male controls. Only one
female FXS subject was included in the study, and interestingly, her urine miR-125a levels were just
slightly above the age-matched control levels.
5. Conclusions
Our study is the first to examine and show disease-specific changes in the urinary miRNA profile
in a neurodevelopmental disorder. Levels of miR-125a were shown to be increased in FXS urine,
consistent with previous observations showing the involvement of FMRP in the regulation of miR-125a
expression. Altered peripheral miRNA levels have been detected in several neuropsychiatric disorders,
including depression, schizophrenia, and ASD [48,49], and increased plasma miR-125a levels were very
recently shown in patients with bipolar disorder and particularly in bipolar manic patients [50]. The
results of the present study demonstrate the potential of urine miRNA profiling for miRNA biomarker
development in FXS. Larger studies are necessary to confirm the abnormalities of urine miR-125a levels
and to explore the impact of the other dysregulated miRNAs observed in urine profiling in FXS.
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